Vedanta Biosciences has raised $50m to enable it to progress drug candidates in a range of autoimmune and infectious diseases. We view Vedanta Biosciences as one of PureTech’s more interesting companies and look forward to the commencement of clinical trials in H1 2017. PureTech is contributing around $30m and its ownership adjusted value will increase by roughly $37m to $120m (75.4% ownership). Vedanta Biosciences now represents 36.5% of PureTech’s $328.7m valuation of its growth stage companie ....
06 Jun 2016
$50m financing for Vedanta Biosciences
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
$50m financing for Vedanta Biosciences
PureTech Health PLC (PRTC:LON) | 224 -5.6 (-1.1%) | Mkt Cap: 605.9m
- Published:
06 Jun 2016 -
Author:
Sheena Berry -
Pages:
3
Vedanta Biosciences has raised $50m to enable it to progress drug candidates in a range of autoimmune and infectious diseases. We view Vedanta Biosciences as one of PureTech’s more interesting companies and look forward to the commencement of clinical trials in H1 2017. PureTech is contributing around $30m and its ownership adjusted value will increase by roughly $37m to $120m (75.4% ownership). Vedanta Biosciences now represents 36.5% of PureTech’s $328.7m valuation of its growth stage companie ....